Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.

Abstract

The clinical efficacy of both oral and parenteral L-ornithine-L-aspartate (OA) was confirmed by randomized, placebo-controlled, double-blind studies in patients with manifest hepatic encephalopathy and hyperammonemia. The drug was able to reduce high blood ammonia levels induced either by ammonium chloride or protein ingestion or existing as a clinical complication of cirrhosis per se. Furthermore, OA improved performance in Number Connection Test-A as well as mental state gradation. In contrast to the positive effects observed in patients with more advanced hepatic encephalopathy, oral OA does not seem to affect minimal hepatic encephalopathy. In a recent trial, OA decreased protein breakdown and stimulated protein synthesis in muscle. The therapy had little side effects, increasing with higher intravenously administered dosages, and was well tolerated after oral and parenteral administration.

• Authors: G Kircheis, M Wettstein, S vom Dahl, D Häussinger
• Journal: Metabolic brain disease (Metab Brain Dis) Vol. 17 Issue 4 Pg. 453-62 (Dec 2002) ISSN: 0885-7490 [Print] United States
• PMID: 12602521 (Publication Type: Journal Article, Review)

Chemical References

• Dipeptides
• Ammonia
• ornithylaspartate

Topics

• Ammonia (blood)
• Dipeptides (therapeutic use)
• Hepatic Encephalopathy (drug therapy, physiopathology)
• Humans
• Liver Cirrhosis (complications)
• Muscular Diseases (drug therapy, etiology)
• Severity of Illness Index